Distribution of aldehyde dehydrogenase 1‐positive stem cells in benign mammary tissue from women with and without breast cancer

Isfoss, Björn L; Holmqvist, Bo; Alm, Per; Olsson, Håkan

doi:10.1111/j.1365-2559.2011.04109.x

Cited by 14 publications

(29 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although contradictory results have been reported for ER expression in CSCs [20], our results for DCIS and IDCs [5] strongly suggest that most CSCs do not express ER or PgR. In addition, we could demonstrate that ALDH1-positive epithelial cells did not overlap with ER- or Ki67-positive epithelial cells in normal breast tissues, as previously reported [21]. These results seem to indicate that CSCs in both DCIS and IDCs as well as stem cells in the normal breast gland have the same characteristics, i.e., most of them are in the G0 phase and unlikely to express ER and PgR.…”

Section: Discussionsupporting

confidence: 76%

Clinicopathological Analysis of Breast Ductal Carcinoma in situ with ALDH1-Positive Cancer Stem Cells

et al. 2013

View full text Add to dashboard Cite

Objective: The aim of this study was to elucidate the clinicopathological characteristics of breast ductal carcinomas in situ (DCIS) with aldehyde dehydrogenase 1 (ALDH1)-positive cancer stem cells (CSCs). Methods: DCIS (n = 194) were subjected to immunohistochemical staining and results were examined for associations with various clinicopathological parameters. The ALDEFLUOR assay for breast cancer cell lines was also performed to determine the proportion of CSCs according to intrinsic subtype. Results: DCIS with ALDH1-positive CSCs were significantly (p < 0.05) more likely to be estrogen receptor-α (ER)-negative, progesterone receptor (PgR)-negative, Ki67-positive and HER2-positive tumors. Luminal A subtype (8.6%) showed a significantly (p < 0.001) lower ALDH1 positivity than the other subtypes [luminal B (50.0%), luminal HER2 (36.8%), HER2 (35.3%) and triple-negative subtype (26.7%)]. Double immunostaining revealed that ALDH1-positive CSCs did not overlap with ER-, PgR- or Ki67-positive tumor cells but did overlap with HER2-positive tumor cells. The percentage of ALDEFLUOR-positive CSCs was lower in the luminal A cell lines (0.02% for T-47D and 0.4% for MCF7) than in the luminal HER2 (9.1% for BT-474 and 9.5% for MDA-MB-361), HER2 (13.9% for AU565 and 33.2% for SK-BR-3) and triple-negative cell lines (28.4% for MDA-MB-231 and 30.7% for MDA-MB-468). Conclusions: Our results suggest that most CSCs in DCIS are in the G0 phase (Ki67 negative) and do not express ER or PgR, but they do express HER2 in HER2-positive tumors.

show abstract

Section: Discussionsupporting

confidence: 76%

Clinicopathological Analysis of Breast Ductal Carcinoma in situ with ALDH1-Positive Cancer Stem Cells

et al. 2013

View full text Add to dashboard Cite

show abstract

“…ALDH1 expression has been detected in benign breast tissue as well as in tumor tissue [31,32]. In tumor tissues, ALDH1 was expressed in both tumor and stromal cells.…”

Section: Discussionmentioning

confidence: 93%

Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer

Kang¹,

Jung

Woo³

et al. 2014

neo

View full text Add to dashboard Cite

Aldehyde dehydrogenase 1 (ALDH1) has been regarded as a breast cancer stem cell marker. Several studies have reported that ALDH1 expression is associated with poor prognosis in breast cancer. We aimed, therefore, to determine the prognostic value of ALDH1 expression and its association with several biomarkers in breast cancer tissue using immunohistochemistry. Furthermore, we investigated the characteristics of and differences between cellular and stromal expression of ALDH1. We performed tissue microarray (TMA) analysis of 425 breast cancer tissue samples collected during surgery. Immunohistochemical staining was then performed to measure the expression of ALDH1 and other breast cancer biomarkers. Statistical analysis of the relationship between ALDH1 expression and clinicopathologic characteristics was performed for 390 TMA samples. We found that ALDH1 was expressed in 71 cases (18.2%) in the tumor cells and/or stroma. Of these cases, 38 (9.7%) showed ALDH1 expression in tumor cells and 38 (9.7%) showed ALDH1 expression in the stroma. ALDH1 expression was significantly associated with markers of a poor prognosis, such as young age, estrogen receptor negativity, progesterone receptor negativity, a high histological grade, and a high Ki-67 index. However, ALDH1 expression was not associated with p53, transforming growth factor-beta, Gli-1, YKL-40, or sonic hedgehog expression status. With regard to the expression site, the clinical characteristics did not differ between cases of cellular expression and those of stromal expression. However, ALDH1 expression in tumor cells was correlated with hormone receptor status, histological grade, molecular subtype, epidermal growth factor receptor expression status, and cytokeratin 5/6 expression status while stromal expression of ALDH1 was only correlated with hormone receptor status. Overall, these findings suggest that ALDH1 expression in tumor tissue is associated with a biologically aggressive phenotype.

show abstract

“…Interestingly, stromal expression has been reported to be present in all cases of benign breast tissue and also to be more common in benign than malignant breast lesions. This may suggest that strong stromal ALDH1A1 expression more resembles normal breast tissue, while the loss of ALDH1A1 represents a more tumour-promoting milieu 22 42. ALDH1A1 expression has been reported in both spindle-shaped cells and round stromal cells, the latter presumed to be mainly lymphocytes 22.…”

Section: Discussionmentioning

confidence: 99%

“…This may suggest that strong stromal ALDH1A1 expression more resembles normal breast tissue, while the loss of ALDH1A1 represents a more tumour-promoting milieu 22 42. ALDH1A1 expression has been reported in both spindle-shaped cells and round stromal cells, the latter presumed to be mainly lymphocytes 22. We therefore chose to evaluate the spindle-shaped cells, presumed to be fibroblasts, as the immune response and number of infiltrating lymphocytes are known prognostic factors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Stem cell biomarker ALDH1A1 in breast cancer shows an association with prognosis and clinicopathological variables that is highly cut-off dependent

et al. 2015

View full text Add to dashboard Cite

show abstract

Distribution of aldehyde dehydrogenase 1‐positive stem cells in benign mammary tissue from women with and without breast cancer

Cited by 14 publications

References 37 publications

Clinicopathological Analysis of Breast Ductal Carcinoma in situ with ALDH1-Positive Cancer Stem Cells

Clinicopathological Analysis of Breast Ductal Carcinoma in situ with ALDH1-Positive Cancer Stem Cells

Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer

Stem cell biomarker ALDH1A1 in breast cancer shows an association with prognosis and clinicopathological variables that is highly cut-off dependent

Contact Info

Product

Resources

About